TCI Wealth Advisors’s Atossa Therapeutics ATOS Stock Holding History

TCI Wealth Advisors’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-27	Closed	–	–	2164
2020 Q4	$0	Buy	+27	New	+$625	﹤0.01%	1536

Other funds holding ATOS

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

TCI Wealth Advisors's ATOS Position: Q1 2021 in Review

TCI Wealth Advisors sold out of Atossa Therapeutics (ATOS) in Q1 2021, closing a stake of 27 shares.

TCI Wealth Advisors first reported a position in ATOS in Q4 2020 and held it in 1 quarter. The position peaked at $0 in Q4 2020. 53 funds tracked by Wall St. Rank hold ATOS as of Q1 2021.

TCI Wealth Advisors reported no remaining Atossa Therapeutics position as of Q1 2021 after selling out during the quarter.
TCI Wealth Advisors sold 27 Atossa Therapeutics shares in Q1 2021.
TCI Wealth Advisors first reported a position in Atossa Therapeutics in Q4 2020 and held it in 1 quarter.
TCI Wealth Advisors's Atossa Therapeutics position peaked at $0 in Q4 2020.
53 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2021.

Based on TCI Wealth Advisors's 13F filing for Q1 2021, filed 29 Apr 2021.